I farmaci biologici nelle malattie infiammatorie croniche intestinali

Translated title of the contribution: Biologic therapy in inflammatory bowel disease

Luisa Spina, Luca Pastorelli, Germana De Nucci, Flaminia Cavallaro, Gian Eugenio Tontini, Nadia Munizio, Maurizio Vecchi

Research output: Contribution to journalArticle

Abstract

The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.

Original languageItalian
Pages (from-to)179-183
Number of pages5
JournalGiornale Italiano di Endoscopia Digestiva
Volume36
Issue number3
Publication statusPublished - Sep 2013

Fingerprint

Biological Therapy
Inflammatory Bowel Diseases
Ulcerative Colitis
Crohn Disease
Safety
Therapeutics
Infliximab
Adalimumab

ASJC Scopus subject areas

  • Gastroenterology
  • Radiology Nuclear Medicine and imaging

Cite this

Spina, L., Pastorelli, L., De Nucci, G., Cavallaro, F., Tontini, G. E., Munizio, N., & Vecchi, M. (2013). I farmaci biologici nelle malattie infiammatorie croniche intestinali. Giornale Italiano di Endoscopia Digestiva, 36(3), 179-183.

I farmaci biologici nelle malattie infiammatorie croniche intestinali. / Spina, Luisa; Pastorelli, Luca; De Nucci, Germana; Cavallaro, Flaminia; Tontini, Gian Eugenio; Munizio, Nadia; Vecchi, Maurizio.

In: Giornale Italiano di Endoscopia Digestiva, Vol. 36, No. 3, 09.2013, p. 179-183.

Research output: Contribution to journalArticle

Spina, L, Pastorelli, L, De Nucci, G, Cavallaro, F, Tontini, GE, Munizio, N & Vecchi, M 2013, 'I farmaci biologici nelle malattie infiammatorie croniche intestinali', Giornale Italiano di Endoscopia Digestiva, vol. 36, no. 3, pp. 179-183.
Spina L, Pastorelli L, De Nucci G, Cavallaro F, Tontini GE, Munizio N et al. I farmaci biologici nelle malattie infiammatorie croniche intestinali. Giornale Italiano di Endoscopia Digestiva. 2013 Sep;36(3):179-183.
Spina, Luisa ; Pastorelli, Luca ; De Nucci, Germana ; Cavallaro, Flaminia ; Tontini, Gian Eugenio ; Munizio, Nadia ; Vecchi, Maurizio. / I farmaci biologici nelle malattie infiammatorie croniche intestinali. In: Giornale Italiano di Endoscopia Digestiva. 2013 ; Vol. 36, No. 3. pp. 179-183.
@article{261ea2547de74494a9e3d95eb4c6a584,
title = "I farmaci biologici nelle malattie infiammatorie croniche intestinali",
abstract = "The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.",
keywords = "Adalimumab, Crohn's disease, Infliximab, Ulcerative colitis",
author = "Luisa Spina and Luca Pastorelli and {De Nucci}, Germana and Flaminia Cavallaro and Tontini, {Gian Eugenio} and Nadia Munizio and Maurizio Vecchi",
year = "2013",
month = "9",
language = "Italian",
volume = "36",
pages = "179--183",
journal = "Giornale Italiano di Endoscopia Digestiva",
issn = "0394-0225",
publisher = "Area Qualita Srl",
number = "3",

}

TY - JOUR

T1 - I farmaci biologici nelle malattie infiammatorie croniche intestinali

AU - Spina, Luisa

AU - Pastorelli, Luca

AU - De Nucci, Germana

AU - Cavallaro, Flaminia

AU - Tontini, Gian Eugenio

AU - Munizio, Nadia

AU - Vecchi, Maurizio

PY - 2013/9

Y1 - 2013/9

N2 - The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.

AB - The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.

KW - Adalimumab

KW - Crohn's disease

KW - Infliximab

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84886010950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886010950&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:84886010950

VL - 36

SP - 179

EP - 183

JO - Giornale Italiano di Endoscopia Digestiva

JF - Giornale Italiano di Endoscopia Digestiva

SN - 0394-0225

IS - 3

ER -